Effect of proton pump inhibitors versus histamine-2 receptor antagonists on acute kidney injury in septic patients at high risk for developing stress ulcers

被引:0
|
作者
Fan, Hua-Ping [1 ]
Zhou, Yu [1 ]
Chen, Mei-Li [2 ]
Qiu, Kun-Hua [3 ]
Feng, Xue [1 ]
Zhou, Chao [1 ]
Zhu, Min-Li [4 ]
Huang, Rong-Zhong [5 ]
Hu, Tian-Yang [5 ]
机构
[1] 63650 Mil Hosp, Dept Cardiol, Xinjiang, Peoples R China
[2] 63650 Mil Hosp, Dept Respirol & Gastroenterol, Xinjiang, Peoples R China
[3] 63650 Mil Hosp, Dept Prevent Med, Xinjiang, Peoples R China
[4] Special Med Ctr Strateg Support Force, Dept Resp Med, Beijing, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 2, Precis Med Ctr, 74 Linjiang Rd, Chongqing 400010, Peoples R China
来源
PHARMACOTHERAPY | 2024年 / 44卷 / 07期
关键词
acute kidney injury; histamine-2 receptor antagonists; proton pump inhibitors; sepsis; stress ulcer prophylaxis; INTERNATIONAL CONSENSUS DEFINITIONS; CRITICALLY-ILL PATIENTS; CLINICAL CHARACTERISTICS; SEPSIS; FAILURE;
D O I
10.1002/phar.2947
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundTo compare the effects of proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) use on the occurrence of acute kidney injury (AKI) in septic patients at high risk for developing stress ulcers.MethodsUsing the Medical Information Mart for Intensive Care IV version 2.2 database, septic patients with high-risk factors for stress ulcers (i.e., shock, coagulopathy, invasive mechanical ventilation, or chronic liver diseases) were included. Exposures included PPIs and H2RAs within 24 h of intensive care unit (ICU) admission or prior to ICU admission. The primary end point was severe sepsis-associated AKI as defined by the Kidney Disease Improving Global Outcomes criteria stage 3 (KDIGO-3). Propensity score matching (PSM) was performed to balance baseline characteristics. Multivariable Cox proportional hazards regression was used to estimate the effect size.Results4731 PPI users and 4903 H2RA users were included. After PSM, there were 1785 pairs exposed to PPIs and H2RAs. In the PSM cohort, the cumulative incident KDIGO-3 rate was higher in the PPI group than in the H2RA group (log-rank test, p = 0.009). Regression analyses showed that PPI exposure [adjusted hazard ratio 1.32, 95% confidence interval (CI) 1.11-1.58, p = 0.002] was associated with incident KDIGO-3 compared with H2RA use. This association remained consistent in sensitivity analyses. Additionally, the PPI group had a higher need for kidney replacement therapy compared with the H2RA group (3.6% vs. 2.1%, P = 0.012).ConclusionsAmong septic patients at high risk for developing stress ulcers, PPI exposure was associated with incident KDIGO-3 AKI compared with H2RA use.
引用
收藏
页码:539 / 548
页数:10
相关论文
共 50 条
  • [31] Proton pump inhibitors vs Histamine-2 receptor antagonists and risk of mortality in critically ill patients - a pilot analysis of multi-institutional study
    Hsieh, Hsing-Chun
    Lin, Tsung-Hsuan
    Lee, Mei-Chuan
    Su, Hui-Chen
    Shao, Shih-Chieh
    Su, Chien-Chou
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 577 - 578
  • [32] Histamine-2 receptor antagonists versus proton pump inhibitors for septic shock after lower gastrointestinal tract perforation: a retrospective cohort study using a national inpatient database
    Suzuki, Jun
    Sasabuchi, Yusuke
    Hatakeyama, Shuji
    Matsui, Hiroki
    Sasahara, Teppei
    Morisawa, Yuji
    Yamada, Toshiyuki
    Yasunaga, Hideo
    JOURNAL OF INTENSIVE CARE, 2020, 8 (01)
  • [33] No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014)
    Landi, Suzanne N.
    Sandler, Robert S.
    Pate, Virginia
    Lund, Jennifer L.
    GASTROENTEROLOGY, 2018, 154 (04) : 861 - +
  • [34] Histamine-2 receptor antagonists versus proton pump inhibitors for septic shock after lower gastrointestinal tract perforation: a retrospective cohort study using a national inpatient database
    Jun Suzuki
    Yusuke Sasabuchi
    Shuji Hatakeyama
    Hiroki Matsui
    Teppei Sasahara
    Yuji Morisawa
    Toshiyuki Yamada
    Hideo Yasunaga
    Journal of Intensive Care, 8
  • [35] Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?: Author's Reply
    Nonaka, Takashi
    Inamori, Masahiko
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 17 (04) : 435 - 435
  • [36] Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study
    Ruigomez, A.
    Johansson, S.
    Nagy, P.
    Rodriguez, L. A. Garcia
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2201 - 2209
  • [37] Incidence of Thrombocytopenia Between Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in Critically Ill, Mechanically Ventilated Patients Receiving Stress-Ulcer Prophylaxis
    Robles, Julian
    Wall, Geoffrey
    Laageide, Leah
    Akhtar, Zaheer
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S314 - S314
  • [38] Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review
    Begg, Maha
    Tarhuni, Mawada
    Fotso, Monique N.
    Gonzalez, Natalie A.
    Sanivarapu, Raghavendra R.
    Osman, Usama
    Kumar, Abishek Latha
    Sadagopan, Aishwarya
    Mahmoud, Anas
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [39] Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
    Weiss, Karl
    Louie, Thomas
    Miller, Mark A.
    Mullane, Kathleen
    Crook, Derrick W.
    Gorbach, Sherwood L.
    BMJ OPEN GASTROENTEROLOGY, 2015, 2 (01):
  • [40] The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: A meta-analysis
    Lin, Pei-Chin
    Chang, Chia-Hsuin
    Hsu, Ping-I
    Tseng, Pi-Lai
    Huang, Yaw-Bin
    CRITICAL CARE MEDICINE, 2010, 38 (04) : 1197 - 1205